Historical Valuation
Akebia Therapeutics Inc (AKBA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.60 is considered Undervalued compared with the five-year average of -2.54. The fair price of Akebia Therapeutics Inc (AKBA) is between 7.90 to 9.46 according to relative valuation methord. Compared to the current price of 1.52 USD , Akebia Therapeutics Inc is Undervalued By 80.76%.
Relative Value
Fair Zone
7.90-9.46
Current Price：1.52
80.76%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Akebia Therapeutics Inc (AKBA) has a current Price-to-Book (P/B) ratio of 9.88. Compared to its 3-year average P/B ratio of 1.35 , the current P/B ratio is approximately 633.26% higher. Relative to its 5-year average P/B ratio of 2.14, the current P/B ratio is about 362.07% higher. Akebia Therapeutics Inc (AKBA) has a Forward Free Cash Flow (FCF) yield of approximately 7.82%. Compared to its 3-year average FCF yield of -16.39%, the current FCF yield is approximately -147.72% lower. Relative to its 5-year average FCF yield of -53.24% , the current FCF yield is about -114.69% lower.
P/B
Median3y
1.35
Median5y
2.14
FCF Yield
Median3y
-16.39
Median5y
-53.24
Competitors Valuation Multiple
AI Analysis for AKBA
The average P/S ratio for AKBA competitors is 33.57, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA.O) exhibits a P/S ratio of 1.60, which is -95.24% above the industry average. Given its robust revenue growth of 57.01%, this premium appears sustainable.
Performance Decomposition
AI Analysis for AKBA
1Y
3Y
5Y
Market capitalization of AKBA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AKBA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AKBA currently overvalued or undervalued?
Akebia Therapeutics Inc (AKBA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.60 is considered Undervalued compared with the five-year average of -2.54. The fair price of Akebia Therapeutics Inc (AKBA) is between 7.90 to 9.46 according to relative valuation methord. Compared to the current price of 1.52 USD , Akebia Therapeutics Inc is Undervalued By 80.76% .
What is Akebia Therapeutics Inc (AKBA) fair value?
AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Akebia Therapeutics Inc (AKBA) is between 7.90 to 9.46 according to relative valuation methord.
How does AKBA's valuation metrics compare to the industry average?
The average P/S ratio for AKBA's competitors is 33.57, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA) exhibits a P/S ratio of 1.60, which is -95.24% above the industry average. Given its robust revenue growth of 57.01%, this premium appears sustainable.
What is the current P/B ratio for Akebia Therapeutics Inc (AKBA) as of Jan 10 2026?
As of Jan 10 2026, Akebia Therapeutics Inc (AKBA) has a P/B ratio of 9.88. This indicates that the market values AKBA at 9.88 times its book value.
What is the current FCF Yield for Akebia Therapeutics Inc (AKBA) as of Jan 10 2026?
As of Jan 10 2026, Akebia Therapeutics Inc (AKBA) has a FCF Yield of 7.82%. This means that for every dollar of Akebia Therapeutics Inc’s market capitalization, the company generates 7.82 cents in free cash flow.
What is the current Forward P/E ratio for Akebia Therapeutics Inc (AKBA) as of Jan 10 2026?
As of Jan 10 2026, Akebia Therapeutics Inc (AKBA) has a Forward P/E ratio of 79.49. This means the market is willing to pay $79.49 for every dollar of Akebia Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Akebia Therapeutics Inc (AKBA) as of Jan 10 2026?
As of Jan 10 2026, Akebia Therapeutics Inc (AKBA) has a Forward P/S ratio of 1.60. This means the market is valuing AKBA at $1.60 for every dollar of expected revenue over the next 12 months.